Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
19.33
-1.07 (-5.25%)
Nov 5, 2026, 4:00 PM EST - Market closed
Anika Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 120.65 | 112.82 | 119.91 | 120.79 | 113.83 | 147.79 | |
Revenue Growth | 5.33% | -5.91% | -0.73% | 6.12% | -22.98% | 13.29% |
Cost of Revenue | 45.65 | 49.01 | 43.3 | 38.26 | 40.61 | 58.39 |
Gross Profit | 75 | 63.81 | 76.6 | 82.53 | 73.22 | 89.41 |
Selling, General & Admin | 50.15 | 49.09 | 55.56 | 59.93 | 51.23 | 74.1 |
Research & Development | 27.45 | 25.77 | 25.54 | 21.76 | 18.32 | 27.33 |
Operating Expenses | 77.6 | 74.86 | 81.1 | 81.69 | 69.55 | 101.42 |
Operating Income | -2.59 | -11.05 | -4.5 | 0.84 | 3.67 | -12.02 |
Interest Expense | - | - | - | - | - | -0.19 |
Interest & Investment Income | 2.21 | 1.74 | 2.34 | 2.31 | 0.65 | - |
EBT Excluding Unusual Items | -0.39 | -9.31 | -2.16 | 3.16 | 4.32 | -12.2 |
Merger & Restructuring Charges | -2.36 | - | -0.61 | - | - | -6.47 |
Other Unusual Items | -0.17 | - | - | - | - | 21.1 |
Pretax Income | -2.91 | -9.31 | -2.76 | 3.16 | 4.32 | 2.43 |
Income Tax Expense | 0.21 | 0.67 | 6.06 | 6.6 | 2.12 | -1.71 |
Earnings From Continuing Operations | -3.12 | -9.98 | -8.83 | -3.44 | 2.2 | 4.13 |
Earnings From Discontinued Operations | -0.66 | -0.9 | -47.56 | -79.23 | -17.06 | - |
Net Income | -3.78 | -10.88 | -56.39 | -82.67 | -14.86 | 4.13 |
Net Income to Common | -3.78 | -10.88 | -56.39 | -82.67 | -14.86 | 4.13 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 14 | 15 | 15 | 15 | 14 |
Shares Outstanding (Diluted) | 14 | 14 | 15 | 15 | 15 | 15 |
Shares Change | -4.23% | -2.60% | 0.44% | 0.65% | -0.50% | 2.90% |
EPS (Basic) | -0.27 | -0.76 | -3.83 | -5.64 | -1.02 | 0.29 |
EPS (Diluted) | -0.28 | -0.76 | -3.83 | -5.64 | -1.02 | 0.28 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.56 | 4.36 | -2.33 | -7.22 | -3.08 | 3.25 |
Free Cash Flow Per Share | 0.04 | 0.30 | -0.16 | -0.49 | -0.21 | 0.22 |
Gross Margin | 62.17% | 56.56% | 63.89% | 68.33% | 64.33% | 60.49% |
Operating Margin | -2.15% | -9.79% | -3.75% | 0.70% | 3.22% | -8.13% |
Profit Margin | -3.14% | -9.64% | -47.02% | -68.44% | -13.05% | 2.80% |
Free Cash Flow Margin | 0.47% | 3.87% | -1.94% | -5.97% | -2.70% | 2.20% |
EBITDA | 3.04 | -5.47 | 1.19 | 6.35 | 9.16 | 2.3 |
EBITDA Margin | 2.52% | -4.85% | 1.00% | 5.26% | 8.04% | 1.56% |
D&A For EBITDA | 5.63 | 5.58 | 5.69 | 5.51 | 5.49 | 14.32 |
EBIT | -2.59 | -11.05 | -4.5 | 0.84 | 3.67 | -12.02 |
EBIT Margin | -2.15% | -9.79% | -3.75% | 0.70% | 3.22% | -8.13% |
Effective Tax Rate | - | - | - | 208.97% | 49.12% | - |